Hospital Da Luz S.A. — Clinical Trial Site

109 Registered trials

42 Currently recruiting

Organisation

Hospital Da Luz S.A.

Location

Lisbon, Portugal

Identifier

ORG-100022819

Address

Avenida Lusiada 100, 1500-650, Portugal

Departments

-
#5708: Serviço Neurologia
035102:Pediatria
2103: Serviço de Oncologia
2710: Serviço Medicina Interna
3108:Medicina Interna
3402: Serviço de Medicina Interna
35102
5801:Oncologia
5803:Oncologia
93149002:Oncología Médica
Cardiologia
Cardiology
Cardiology Department
Centro de Oncologia
Departamento de Oncologia
Department of Internal Medicine
Gastroenterology
Gastroenterology Department
Hematology
Internal Medicine
Medical Oncology
n/a
Nephrology
Neurology
Neurology Service
Oncologia
Oncology
Oncology Department
Piso-1
Serviço de Cardiologia
Serviço de Endocrinologia
Serviço de Gastroenterologia
Serviço de Hematologia
Serviço de Medicina Interna
Servico de Neurologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria
Serviço Hematologia
Serviço Neurologia
Servio de Oncologia

Clinical trials at this site (109)

Search interface

Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended

2024-514343-29-00 multiple sclerosis 5 2024-11-19
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymph 5 2024-09-03
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 High-risk Large B-cell Lymphoma 5 2024-07-31
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
STEP Young: A research study on how well semaglutide helps children and teenagers with excess body weight lose weight Ended

2022-502922-41-00 Obesity and overweight 5 2023-07-03
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Metastatic Colorectal Cancer 5 2022-12-22
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26